AWS
HUMA icon

Atria Wealth Solutions’s Humacyte HUMA Stock Holding History

Atria Wealth Solutions’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-25,840
Closed -$130K – 1962
2024
Q4 		$130K Buy
+25,840
New +$128K ﹤0.01% 1880

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Atria Wealth Solutions's HUMA Position: Q1 2025 in Review

Atria Wealth Solutions sold out of Humacyte (HUMA) in Q1 2025, closing a stake of 25,840 shares — an estimated $130K sold.

Atria Wealth Solutions first reported a position in HUMA in Q4 2024 and held it in 1 quarter. The position peaked at $130K in Q4 2024. 168 funds tracked by Wall St. Rank hold HUMA as of Q1 2025.

  • Atria Wealth Solutions reported no remaining Humacyte position as of Q1 2025 after selling out during the quarter.
  • Atria Wealth Solutions sold 25,840 Humacyte shares in Q1 2025, an estimated $130K.
  • Atria Wealth Solutions first reported a position in Humacyte in Q4 2024 and held it in 1 quarter.
  • Atria Wealth Solutions's Humacyte position peaked at $130K in Q4 2024.
  • 168 funds tracked by Wall St. Rank held Humacyte as of Q1 2025.

Based on Atria Wealth Solutions's 13F filing for Q1 2025, filed 9 May 2025.